Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Progression-Free Survival Is Meaningful Endpoint For Glioma Trials

Executive Summary

Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed

You may also be interested in...



Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint

FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.

Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte

The heterogeneity of pediatric brain tumors generally precludes the use of non-inferiority trials to support approval, FDA's Pediatric Oncology Subcommittee determined

Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte

The heterogeneity of pediatric brain tumors generally precludes the use of non-inferiority trials to support approval, FDA's Pediatric Oncology Subcommittee determined

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel